EP 2515930 A1 20121031 - METHODS AND COMPOSITIONS RELATED TO REDUCED MET PHOSPHORYLATION BY LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2 IN TUMOR CELLS
Title (en)
METHODS AND COMPOSITIONS RELATED TO REDUCED MET PHOSPHORYLATION BY LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2 IN TUMOR CELLS
Title (de)
VERFAHREN UND ZUSAMMENSETZUNGEN IM ZUSAMMENHANG MIT REDUZIERTER MET-PHOSPHORYLIERUNG DURCH AUS LEUKOZYTEN GEWONNENES CHEMOTAXIN 2 IN TUMORZELLEN
Title (fr)
MÉTHODES ET COMPOSITIONS BASÉES SUR LA PHOSPHORYLATION RÉDUITE DE MET PAR LA CHIMIOTAXINE 2 DÉRIVÉE DES CELLULES LEUCOCYTAIRES DANS DES CELLULES TUMORALES
Publication
Application
Priority
- US 28862709 P 20091221
- CN 2010079993 W 20101220
Abstract (en)
[origin: WO2011076095A1] It was discovered that leukocyte cell-derived chemotaxin 2 (LECT2) correlated with down-regulated vascular invasion in HCC patients. It was also found that LECT2 strongly reduced the growth, migration and invasiveness of HCC cells via inhibition of the phosphorylation of Met and other downstream targets in the HGF/MET pathway. The HXXXD motif of LECT2 was found to be important for its tumor inhibition mechanism. LECT2 reduced Met tyrosine phosphorylation and tumor cell invasion in other cancers, such as lung, breast, and gastric cancers, in addition to HCC. Methods and compositions for preventing, treating or diagnosing tumors, such as HCC, based on the newly discovered tumor suppression property of LECT2 are described.
IPC 8 full level
A61K 38/19 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP)
A61K 38/195 (2013.01); A61P 35/00 (2017.12)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2011076095 A1 20110630; WO 2011076095 A8 20110929; CN 102802658 A 20121128; EP 2515930 A1 20121031; EP 2515930 A4 20130410; TW 201200151 A 20120101
DOCDB simple family (application)
CN 2010079993 W 20101220; CN 201080058733 A 20101220; EP 10838658 A 20101220; TW 99144950 A 20101221